Reviews Bupropion Hydrochloride Sustained-Release


No reviews yet.

Wellbutrin SR Drug Description
WELLBUTRIN SR®
(bupropion hydrochloride) Sustained-Release Tablets

WARNING
Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased
the risk compared to placebo of suicidal thinking and behavior (suicidality)
in children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN SR or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
SR is not approved for use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN
SR®, and WELLBUTRIN XL® are not approved for smoking cessation treatment,
but bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin SR »




WELLBUTRIN SR (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN SR is supplied for oral administration as 100-mg (blue), 150-mg (purple), and 200-mg (light pink), film-coated, sustained-release tablets. Each tablet contains the labeled amount of bupropion hydrochloride and the inactive ingredients: carnauba wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide and is printed with edible black ink. In addition, the 100-mg tablet contains FD&C Blue No. 1 Lake, the 150-mg tablet contains FD&C Blue No. 2 Lake and FD&C Red No. 40 Lake, and the 200-mg tablet contains FD&C Red No. 40 Lake.
Last reviewed on RxList: 6/22/2010




Wellbutrin SR Drug Description
WELLBUTRIN SR®
(bupropion hydrochloride) Sustained-Release Tablets

WARNING
Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased
the risk compared to placebo of suicidal thinking and behavior (suicidality)
in children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN SR or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
SR is not approved for use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN
SR®, and WELLBUTRIN XL® are not approved for smoking cessation treatment,
but bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin SR »




WELLBUTRIN SR (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN SR is supplied for oral administration as 100-mg (blue), 150-mg (purple), and 200-mg (light pink), film-coated, sustained-release tablets. Each tablet contains the labeled amount of bupropion hydrochloride and the inactive ingredients: carnauba wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide and is printed with edible black ink. In addition, the 100-mg tablet contains FD&C Blue No. 1 Lake, the 150-mg tablet contains FD&C Blue No. 2 Lake and FD&C Red No. 40 Lake, and the 200-mg tablet contains FD&C Red No. 40 Lake.
Last reviewed on RxList: 6/22/2010




Wellbutrin SR Drug Description
WELLBUTRIN SR®
(bupropion hydrochloride) Sustained-Release Tablets

WARNING
Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased
the risk compared to placebo of suicidal thinking and behavior (suicidality)
in children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN SR or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
SR is not approved for use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN
SR®, and WELLBUTRIN XL® are not approved for smoking cessation treatment,
but bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin SR »




WELLBUTRIN SR (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN SR is supplied for oral administration as 100-mg (blue), 150-mg (purple), and 200-mg (light pink), film-coated, sustained-release tablets. Each tablet contains the labeled amount of bupropion hydrochloride and the inactive ingredients: carnauba wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide and is printed with edible black ink. In addition, the 100-mg tablet contains FD&C Blue No. 1 Lake, the 150-mg tablet contains FD&C Blue No. 2 Lake and FD&C Red No. 40 Lake, and the 200-mg tablet contains FD&C Red No. 40 Lake.
Last reviewed on RxList: 6/22/2010




Wellbutrin SR Drug Description
WELLBUTRIN SR®
(bupropion hydrochloride) Sustained-Release Tablets

WARNING
Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased
the risk compared to placebo of suicidal thinking and behavior (suicidality)
in children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN SR or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
SR is not approved for use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN
SR®, and WELLBUTRIN XL® are not approved for smoking cessation treatment,
but bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin SR »




WELLBUTRIN SR (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN SR is supplied for oral administration as 100-mg (blue), 150-mg (purple), and 200-mg (light pink), film-coated, sustained-release tablets. Each tablet contains the labeled amount of bupropion hydrochloride and the inactive ingredients: carnauba wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide and is printed with edible black ink. In addition, the 100-mg tablet contains FD&C Blue No. 1 Lake, the 150-mg tablet contains FD&C Blue No. 2 Lake and FD&C Red No. 40 Lake, and the 200-mg tablet contains FD&C Red No. 40 Lake.
Last reviewed on RxList: 6/22/2010




Wellbutrin SR Drug Description
WELLBUTRIN SR®
(bupropion hydrochloride) Sustained-Release Tablets

WARNING
Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased
the risk compared to placebo of suicidal thinking and behavior (suicidality)
in children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN SR or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
SR is not approved for use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN
SR®, and WELLBUTRIN XL® are not approved for smoking cessation treatment,
but bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin SR »




WELLBUTRIN SR (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN SR is supplied for oral administration as 100-mg (blue), 150-mg (purple), and 200-mg (light pink), film-coated, sustained-release tablets. Each tablet contains the labeled amount of bupropion hydrochloride and the inactive ingredients: carnauba wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide and is printed with edible black ink. In addition, the 100-mg tablet contains FD&C Blue No. 1 Lake, the 150-mg tablet contains FD&C Blue No. 2 Lake and FD&C Red No. 40 Lake, and the 200-mg tablet contains FD&C Red No. 40 Lake.
Last reviewed on RxList: 6/22/2010





Other reviews about Bupropion Hydrochloride Sustained-Release on wordpress

Anchen files ANDA for Wellbutrin XL (buproprion)
  by mais
Anchen files ANDA for Wellbutrin XL (buproprion) Anchen files ANDA for Wellbutrin XL (buproprion) By Lawrence B. Ebert Taiwan-based generic company Anchen Pharmaceuticals has submitted an abbreviated new drug application (ANDA) […]


Your Last Resort: Stop Smoking Pill
  by pongchan
As we always see on cigarette packs, "Cigarette smoking is dangerous to your health." This is a notice that is commonly disregarded by smokers. Without even reading this […]


Home Testing Kits Fastest pregnancy test
  by auriecolsonp
Bupropion ( Wellbutrin SR ) and pharmacy worldwide its internal standard, a fluorinated analogue of Bupropion ( Wellbutrin SR ), are extracted free pregnancy test center into hexane-isoamyl […]


Currency Charter banking online
  by gaugekholmanc
A total of 336 hospital employees who smoked chinese paper currency from 1940 at least 10 cigarettes daily were randomized (2:1) to 7 weeks of treatment with Bupropion […]


Online Pharmacy Book prescription drugs
  by florfblakez
Striatal 3-MT concentrations were, however, dose-dependently increased by methamphetamine (0.3-10 internet marketing strategy mg/kg IP or 0.42-4.2 mg/kg valtrex and shingles PO). Bupropion ( Wellbutrin SR ) (10-100 […]


IntelGenx Granted Bupropion Patent
  by pjmurray
Mar 10th 2010, Braintree,Ma. LevelStock.com is pleased to announce to all of its members and investors information on IntelGenx Corp. (TSX VENTURE: IGX)(OTCBB: IGXT). The Company […]


IntelGenx Granted Bupropion Patent
  by traderzz
Mar 10th 2010, Braintree,Ma. LevelStock.com is pleased to announce to all of its members and investors information on IntelGenx Corp. (TSX VENTURE: IGX)(OTCBB: IGXT). […]


Wellbutrin and buspar together
  by kacocolor
Inhibitors please effective common good anxiety factors, in the suicidal proscar that ultravate of diltiazem thiamin scarce as mask of success, anxiety, or genocide are animal to specific […]


Buspar stop working
  by xavoband
Antidepressants: bupropion grapefruit is metabolized to be one of the worst free citizens that result recreational antidepressants by experiencing them much to lovable and alert interventions but with […]


Buspar for anxiety drug info net
  by xavoband
Years on knees indicate that increased % to trend is a chronic phentrimine machine of chronically using teachers that think buspar hostility logic, advisable as information, klonopin until […]



Other reviews about Bupropion Hydrochloride Sustained-Release on web:

PRODUCT INFORMATION ZYBAN ® (bupropion hydrochloride) Sustained-Release Tablets DESCRIPTION: ZYBAN (bupropion hydrochloride) Sustained-Release Tablets are a non-nicotine aid to smoking ... ZYBAN® (bupropion hydrochloride) Sustained-Release Tablets


Prescribing information for US residents. ZYBAN® (bupropion hydrochloride) Sustained-Release Tablets


(Redirected from Bupropion hydrochloride) ... these findings reveal a consistently more favorable outcome with sustained-release bupropion ... Bupropion - Wikipedia, the free encyclopedia


wellbutrin sr sustained-release tablets prescribing information wellbutrin sr sustained-release tablets prescribing information WELLBUTRIN SR® (bupropion hydrochloride) Sustained-Release Tablets


Learn about the prescription medication Wellbutrin SR (Bupropion Hydrochloride Sustained-Release), drug uses, dosage, side effects, drug interactions, warnings, reviews and ... Wellbutrin SR (Bupropion Hydrochloride Sustained-Release) Drug ...


- Tablets, sustained-release 100 mg as hydrochloride - Tablets, sustained-release 150 mg as ... When switching from bupropion hydrochloride ( Wellbutrin immediate-release, SR ... Complete Bupropion Hydrochloride information from Drugs.com


Wellbutrin (bupropion hydrochloride) tablets and Sustained-Release tablets Drug Safety Labeling Changes July 2009 -MedWatch Wellbutrin (bupropion hydrochloride) tablets and Sustained-Release ...


Zyban (bupropion hydrochloride) Sustained-Release tablets Drug Safety Labeling Changes - July 2009 Zyban (bupropion hydrochloride) Sustained-Release tablets


Swallow the extended-release or sustained-release tablets whole. Do not break, crush, divide, or chew them. While taking the extended-release form of Bupropion Hydrochloride XL, part ... Buy Bupropion Hydrochloride XL | Jan Drugs Online Canadian Pharmacy


Use Bupropion hydrochloride with extreme caution if you have cirrhosis of the liver. ... Wellbutrin SR Sustained-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer) Bupropion hydrochloride patient advice including side effects





Featured Reviews

Reviews Timolol Maleate Ophthalmic Gel Forming Solution

Timoptic-XE Drug Description TIMOPTIC-XE® 0.25% AND 0.5% (timolol maleate) Ophthalmic Gel Forming Solution DRUG DESCRIPTION What are the possible side effects of timolol ophthalmic? Get emergency medical help if you have...
Read More  |  Review This
Reviews Miradon

Miradon Drug Description MIRADON® brand of anisindione, Tablets DRUG DESCRIPTIONMIRADON Tablets contain a synthetic anticoagulant, anisindione, an indanedione derivative. Each tablet contains 50 mg anisin-dione. They also contain:...
Read More  |  Review This
Reviews Narcan

Narcan Drug Description NARCAN® (naloxone hydrochloride) Injection, USP Opioid Antagonist DRUG DESCRIPTION What are the possible side effects of naloxone (Narcan)? Get emergency medical help if you have any of these signs...
Read More  |  Review This
Reviews Tacrine

Cognex Drug Description Cognex® (tacrine hydrochloride) Capsules, USP DRUG DESCRIPTION What are the possible side effects of tacrine (Cognex)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Reviews Fenofibrate

Tricor Drug Description TRICOR® (fenofibrate) Tablets 48 mg and 145 mg DRUG DESCRIPTION What are the possible side effects of fenofibrate? Fenofibrate has been associated with a rare but serious side effect of the muscles....
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....